Overview

HDM201 Added to CT in R/R or Newly Diagnosed AML

Status:
Withdrawn

Trial end date:
2023-06-13

Target enrollment:

Participant gender:

Summary

This is a multi-center open-label Phase I/II study investigating orally administered HDM201 in combination with chemotherapy in two populations: subjects with first line AML or subjects with relapsed/refractory AML. This study is conducted in three parts: dose escalation, dose expansion and DDI study.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Cytarabine
Daunorubicin
Idarubicin
Midazolam
Midostaurin
Posaconazole
Staurosporine